A pharmacological overview of aprepitant for the prevention of postoperative nausea and vomiting

References

• Myles PS, Williams DL, Hendrata M, et al. Patient satisfaction after anaesthesia and surgery: results of a prospective survey of 10,811 patients. Br J Anaesth. 2000 Jan;84(1):6–10.
   PubMed Web of Science ®Google Scholar
• Eberhart LH, Mauch M, Morin AM, et al. Impact of a multimodal anti-emetic prophylaxis on patient satisfaction in high-risk patients for postoperative nausea and vomiting. Anaesthesia. 2002 Oct;57(10):1022–1027.
   PubMed Web of Science ®Google Scholar
• Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020 Aug;131(2):411–448. DOI:10.1213/ANE.0000000000004833
   PubMed Web of Science ®Google Scholar
• Apfel CC, Läärä E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999 Sep;91(3):693–700.
   PubMed Web of Science ®Google Scholar
• Habib AS, Chen YT, Taguchi A, et al. Postoperative nausea and vomiting following inpatient surgeries in a teaching hospital: a retrospective database analysis. Curr Med Res Opin. 2006 Jun;22(6):1093–1099.
   PubMed Web of Science ®Google Scholar
• Hill RP, Lubarsky DA, Phillips-Bute B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology. 2000 Apr;92(4):958–967.
   PubMed Web of Science ®Google Scholar
• Dzwonczyk R, Weaver TE, Puente EG, et al. Postoperative nausea and vomiting prophylaxis from an economic point of view. Am J Ther. 2012 Jan;19(1):11–15.
   PubMed Web of Science ®Google Scholar
• Caughey AB, Wood SL, Macones GA, et al. Guidelines for intraoperative care in cesarean delivery: enhanced recovery after surgery society Recommendations (Part 2). Am J Obstet Gynecol. 2018 Dec;219(6):533–544.
   PubMed Web of Science ®Google Scholar
• Diemunsch P, Joshi GP, Brichant JF. Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting. Br J Anaesth. 2009 Jul;103(1):7–13. DOI:10.1093/bja/aep125
   PubMed Web of Science ®Google Scholar
• Hornby PJ. Central neurocircuitry associated with emesis. Am j med. 2001 Dec 3;111(8):106s–112s.
   PubMedGoogle Scholar
• Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs. 2009;69(13):1853–1878.
   PubMed Web of Science ®Google Scholar
• Weibel S, Schaefer MS, Raj D, et al. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: an abridged Cochrane network meta-analysis. Anaesthesia. 2021 Jul;76(7):962–973. DOI:10.1111/anae.15295
   PubMed Web of Science ®Google Scholar
• Carpenter DO, Briggs DB, Strominger N. Peptide-induced emesis in dogs. Behav Brain Res. 1984 Mar;11(3):277–281.
   PubMed Web of Science ®Google Scholar
• Watson JW, Gonsalves SF, Fossa AA, et al. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol. 1995 May;115(1):84–94.
   PubMed Web of Science ®Google Scholar
• Kris MG, Radford JE, Pizzo BA, et al. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst. 1997 Jun 4;89(11):817–818. DOI:10.1093/jnci/89.11.817
   PubMedGoogle Scholar
• Gesztesi Z, Scuderi Phillip E, White Paul F, et al. Substance P (Neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology. 2000;93(4):931–937. DOI:10.1097/00000542-200010000-00009
   PubMed Web of Science ®Google Scholar
• Food and drug administration (FDA): highlights of prescribing information - aprepitant.2010.
   Google Scholar
• Food and drug administration (FDA): highlights of prescribing information - Aponvie (aprepitant).2022.
   Google Scholar
• Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287–1292.
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Marbury T, Fosbinder T, et al. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clin Pharmacokinet. 2005;44(6):637–647. DOI:10.2165/00003088-200544060-00005
   PubMed Web of Science ®Google Scholar
• Majumdar AK, Howard L, Goldberg MR, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol. 2006;46(3):291–300. DOI:10.1177/0091270005283467
   PubMed Web of Science ®Google Scholar
• Salman FT, DiCristina C, Chain A, et al. Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects. J Pediatr Surg. 2019 Jul;54(7):1384–1390.
   PubMed Web of Science ®Google Scholar
• Kanaparthi A, Kukura S, Slenkovich N, et al. Perioperative Administration of Emend(®) (aprepitant) at a tertiary care children’s hospital: a 12-month survey. Clin Pharmacol. 2019;11:155–160.
   PubMed Web of Science ®Google Scholar
• Karthaus M, Schiel X, Ruhlmann CH, et al. Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults. Expert Rev Clin Pharmacol. 2019 Jul;12(7):661–680.
   PubMed Web of Science ®Google Scholar
• SC YA, Yuan N, Ottoboni T, editor Phase 1 bioavailability study of HTX-019 intravenous injection compared with aprepitant oral capsules. American Society of Anesthesiologists 2022 Annual meeting: p. A4284. http://www.asaabstracts.com/strands/asaabstracts/abstract.htm?year=2022&index=17&absnum=6732
   Google Scholar
• Kakade P, Pathan Z, Gite S, et al. Nanoparticle engineering of aprepitant using nano-by-design (NbD) Approach. AAPS Pharm Sci Tech. 2022 2022 JUL 28;23(6):204. DOI:10.1208/s12249-022-02350-5.
   PubMed Web of Science ®Google Scholar
• Roos C, Dahlgren D, Berg S, et al. In Vivo mechanisms of intestinal drug absorption from aprepitant nanoformulations. Mol Pharm. 2017 Dec 4;14(12):4233–4242. DOI:10.1021/acs.molpharmaceut.7b00294
   PubMedGoogle Scholar
• Tattersall FD, Rycroft W, Francis B, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology. 1996;35(8):1121–1129. DOI:10.1016/S0028-3908(96)00020-2
   PubMed Web of Science ®Google Scholar
• Bergström M, Hargreaves RJ, Burns HD, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry. 2004 May 15;55(10):1007–1012. DOI:10.1016/j.biopsych.2004.02.007
   PubMed Web of Science ®Google Scholar
• Gan TJ, Apfel CC, Kovac A, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg. 2007 May;104(5):1082–1089. DOI:10.1213/01.ane.0000263277.35140.a3
   PubMed Web of Science ®Google Scholar
• Diemunsch P, Gan TJ, Philip BK, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth. 2007 Aug;99(2):202–211. DOI:10.1093/bja/aem133.
   PubMed Web of Science ®Google Scholar
• Diemunsch P, Apfel C, Gan TJ, et al. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant. Curr Med Res Opin. 2007 Oct;23(10):2559–2565.
   PubMed Web of Science ®Google Scholar
• Jeyabalan S, Thampi SM, Karuppusami R, et al. Comparing the efficacy of aprepitant and ondansetron for the prevention of postoperative nausea and vomiting (PONV): a double blinded, randomised control trial in patients undergoing breast and thyroid surgeries. Indian J Anaesth. 2019 Apr;63(4):289–294.
   PubMed Web of Science ®Google Scholar
• Moon HY, Baek CW, Choi GJ, et al. Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial. BMC Anesthesiol. 2014;14(1):68. DOI:10.1186/1471-2253-14-68
   PubMedGoogle Scholar
• Kakuta N, Tsutsumi YM, Horikawa YT, et al. Neurokinin-1 receptor antagonism, aprepitant, effectively diminishes post-operative nausea and vomiting while increasing analgesic tolerance in laparoscopic gynecological procedures. J Med Invest. 2011 Aug;58(3–4):246–251.
   PubMedGoogle Scholar
• Jung WS, Kim YB, Park HY, et al. Oral administration of aprepitant to prevent postoperative nausea in highly susceptible patients after gynecological laparoscopy. J Anesth. 2013 Jun;27(3):396–401.
   PubMed Web of Science ®Google Scholar
• Alonso-Damián ER, Anguiano-García MM. Aprepitant versus ondansetron in preventing postoperative nausea and vomiting in patients undergoing open cholecystectomy. Rev Mex Anestesiol. 2012;35(1):8–14.
   Google Scholar
• Tsutsumi YM, Kakuta N, Soga T, et al. The effects of intravenous fosaprepitant and ondansetron for the prevention of postoperative nausea and vomiting in neurosurgery patients: a prospective, randomized, double-blinded study. BioMed Res Int. 2014;2014:307025.
   PubMed Web of Science ®Google Scholar
• Soga T, Kume K, Kakuta N, et al. Fosaprepitant versus ondansetron for the prevention of postoperative nausea and vomiting in patients who undergo gynecologic abdominal surgery with patient-controlled epidural analgesia: a prospective, randomized, double-blind study. J Anesth. 2015 Oct;29(5):696–701.
   PubMed Web of Science ®Google Scholar
• Kakuta N, Kume K, Hamaguchi E, et al. The effects of intravenous fosaprepitant and ondansetron in the prevention of postoperative nausea and vomiting in patients who underwent lower limb surgery: a prospective, randomized, double-blind study. J Anesth. 2015 Dec;29(6):836–841.
   PubMed Web of Science ®Google Scholar
• Habib AS, Keifer JC, Borel CO, et al. A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy. Anesth Analg. 2011 Apr;112(4):813–818. DOI:10.1213/ANE.0b013e3181ff47e2
   PubMed Web of Science ®Google Scholar
• Bilgen S, Kızılcık N, Haliloğlu M, et al. Effect of the dexamethasone-ondansetron combination versus dexamethasone-aprepitant combination to prevent postoperative nausea and vomiting. Turk J Anaesthesiol Reanim. 2018 Sep;46(5):373–380.
   PubMed Web of Science ®Google Scholar
• Kawano H, Matsumoto T, Hamaguchi E, et al. Antiemetic efficacy of combined aprepitant and dexamethasone in patients at high-risk of postoperative nausea and vomiting from epidural fentanyl analgesia. Minerva Anestesiol. 2015 Apr;81(4):362–368.
   PubMed Web of Science ®Google Scholar
• Vallejo MC, Phelps AL, Ibinson JW, et al. Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery. Plast Reconstr Surg. 2012 Feb;129(2):519–526.
   PubMed Web of Science ®Google Scholar
• Ham SY, Shim YH, Kim EH, et al. Aprepitant for antiemesis after laparoscopic gynaecological surgery: a randomised controlled trial. Eur J Anaesthesiol. 2016 Feb;33(2):90–95.
   PubMed Web of Science ®Google Scholar
• Sinha AC, Singh PM, Williams NW, et al. Aprepitant’s prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2014 Feb;24(2):225–231.
   PubMed Web of Science ®Google Scholar
• Lim CS, Ko YK, Kim YH, et al. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting. Korean J Anesthesiol. 2013 Mar;64(3):212–217.
   PubMedGoogle Scholar
• Lee SJ, Lee SM, Kim SI, et al. The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone. Korean J Anesthesiol. 2012 Sep;63(3):221–226.
   PubMedGoogle Scholar
• Choi EK, Kim DG, Jeon Y. Comparison of the prophylactic antiemetic efficacy of aprepitant plus palonosetron versus aprepitant plus ramosetron in patients at high risk for postoperative nausea and vomiting after laparoscopic cholecystectomy: a prospective randomized-controlled trial. Surg Laparosc Endosc Percutan Tech. 2016 Oct;26(5):354–357.
   PubMed Web of Science ®Google Scholar
• Yoo JH, Kim SI, Chung JW, et al. Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia. Korean J Anesthesiol. 2018 Dec;71(6):440–446.
   PubMed Web of Science ®Google Scholar
• Green MS, Green P, Malayaman SN, et al. Randomized, double-blind comparison of oral aprepitant alone compared with aprepitant and transdermal scopolamine for prevention of postoperative nausea and vomiting. Br J Anaesth. 2012 Nov;109(5):716–722.
   PubMed Web of Science ®Google Scholar
• Bergese SD, Puente EG, Antor MA, et al. A prospective, randomized, double-blinded, double-dummy pilot study to assess the preemptive effect of triple therapy with aprepitant, dexamethasone, and promethazine versus ondansetron, dexamethasone and promethazine on reducing the incidence of postoperative nausea and vomiting experienced by patients undergoing craniotomy under general anesthesia. Front Med. 2016;3:29.
   PubMed Web of Science ®Google Scholar
• de Morais LC, Sousa AM, Flora GF, et al. Aprepitant as a fourth antiemetic prophylactic strategy in high-risk patients: a double-blind, randomized trial. Acta Anaesthesiol Scand. 2018 Apr;62(4):483–492.
   PubMed Web of Science ®Google Scholar
• Thanuja IL, Parida S, Mishra SK, et al. Effect of combinations of dexamethasone-ondansetron and dexamethasone-ondansetron-aprepitant versus aprepitant alone for early postoperative nausea and vomiting after day care gynaecological laparoscopy: a randomised clinical trial. Indian J Anaesth. 2021 Jun;65(6):465–470.
   PubMed Web of Science ®Google Scholar
• Spaniolas K, Nie L, Moller D, et al. A comprehensive approach for the prevention of nausea and vomiting following sleeve gastrectomy: a Randomized Controlled Trial. Obes Surg. 2020 Nov;30(11):4250–4257.
   PubMed Web of Science ®Google Scholar
• Grigio TR, Sousa AM, Magalhães GGN, et al. Aprepitant plus palonosetron for the prevention of postoperative nausea and vomiting after breast cancer surgery: a double blind, randomized trial. Clinics (Sao Paulo). 2020;75:e1688.
   PubMed Web of Science ®Google Scholar
• Atsuta J, Inoue S, Tanaka Y, et al. Fosaprepitant versus droperidol for prevention of PONV in craniotomy: a randomized double-blind study. J Anesth. 2017 Feb;31(1):82–88.
   PubMed Web of Science ®Google Scholar
• Singh PM, Borle A, Rewari V, et al. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J. 2016 Feb;92(1084):87–98.
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang H, Du BX, et al. Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysis. Medicine (Baltimore). 2015 May;94(19):e762.
   PubMed Web of Science ®Google Scholar
• Murakami C, Kakuta N, Satomi S, et al. Neurokinin-1 receptor antagonists for postoperative nausea and vomiting: a systematic review and meta-analysis. Braz J Anesthesiol. 2020 Sep;70(5):508–519.
   PubMedGoogle Scholar
• Cavaye J, Dai B, Gurunathan K, et al. NK1 receptor antagonists versus other antiemetics in the prevention of postoperative nausea and vomiting following laparoscopic surgical procedures: a systematic review and meta-analysis. J Anaesthesiol Clin Pharmacol. 2022 Jan;38(1):35–47.
   PubMed Web of Science ®Google Scholar
• Qiu T, Men P, Sun T, et al. Cost-effectiveness of aprepitant in preventing chemotherapy-induced nausea and vomiting: a systematic review of published articles. Front Public Health. 2021;9:660514.
   PubMed Web of Science ®Google Scholar